Rationally designed tularemia vaccines

Expert Review of Vaccines

Volumn 8, Issue 7, 2009, Pages 877-885

  Mann, Barbara J ^a   Ark, Nicole M ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Biological warfare; Francisella tularensis; Tularemia

Indexed keywords

BACTERIAL ANTIGEN; FREUND ADJUVANT; LIVE VACCINE; OUTER MEMBRANE PROTEIN; TETANUS TOXOID; TULAREMIA VACCINE;

ANTIBODY RESPONSE; ANTIGEN EXPRESSION; BACTERIAL STRAIN; BACTERIAL TRANSMISSION; BACTERIAL VIRULENCE; BACTERIUM MUTANT; BIOLOGICAL WARFARE; FRANCISELLA TULARENSIS; HUMAN; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; TULAREMIA; VACCINE PRODUCTION;

BACTERIAL VACCINES; DRUG DESIGN; FRANCISELLA TULARENSIS; HUMANS; TULAREMIA; VACCINES, ATTENUATED;

EID: 67650456778     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.09.51     Document Type: Review

References (55)

1. Tarnvik A, Berglund L. Tularaemia. Eur. Respir. J. 21(2), 361-373 (2003). • Provides a concise review of the clinical aspects of tularemia.
2. Eliasson H, Broman T, Forsman M, Back E. Tularemia: current epidemiology and disease management. Infect. Dis. Clin. North Am. 20, 289-311 (2006). (Pubitemid 44177423)
3. Johansson A, Farlow J, Larsson P et al. Worldwide genetic relationships among Francisella tularensis isolates determined by multiple-locus variable-number tandem repeat ana lysis. J. Bacteriol. 186(17), 5808-5818 (2004). (Pubitemid 39128654)
4. Broekhuijsen M, Larsson P, Johansson A et al. Genome-wide DNA microarray ana lysis of Francisella tularensis strains demonstrates extensive genetic conservation within the species but identifies regions that are unique to the highly virulent F. tularensis subsp. tularensis. J. Clin. Microbiol. 41(7), 2924-2931 (2003). (Pubitemid 36842280)
5. Rohmer L, Brittnacher M, Svensson K et al. Potential source of Francisella tularensis live vaccine strain attenuation determined by genome comparison. Infect. Immun. 74(12), 6895-6906 (2006). • Provides comprehensive genome comparisons of Francisella tularensis subspecies novicida U112, holarctica live vaccine strain (LVS) and tularensis Schu S4. (Pubitemid 44913165)
6. Petrosino JF, Xiang Q, Karpathy SE et al. Chromosome rearrangement and diversification of Francisella tularensis revealed by the type B (OSU18) genome sequence. J. Bacteriol. 188(19), 6977-6985 (2006). (Pubitemid 44497910)
7. Rohmer L, Fong C, Abmayr S et al. Comparison of Francisella tularensis genomes reveals evolutionary events associated with the emergence of human pathogenic strains. Genome Biol. 8(6), R102 (2007). (Pubitemid 351903178)
8. Conlan JW, Oyston PC. Vaccines against Francisella tularensis. Ann. NY Acad. Sci. 1105, 325-350 (2007).
9. Hornick RB, Eigelsbach HT. Aerogenic immunization of man with live tularemia vaccine. Bacteriol. Rev. 30(3), 532-538 (1966).
10. Conlan JW, North RJ. Early pathogenesis of infection in the liver with the facultative intracellular bacteria Listeria monocytogenes, Francisella tularensis, and Salmonella typhimurium involves lysis of infected hepatocytes by leukocytes. Infect. Immun. 60(12), 5164-5171 (1992).
11. Forestal CA, Benach JL, Carbonara C, Italo JK, Lisinski TJ, Furie MB. Francisella tularensis selectively induces proinflammatory changes in endothelial cells. J. Immunol. 171(5), 2563-2570 (2003). (Pubitemid 37025567)
12. Golovliov I, Baranov V, Krocova Z, Kovarova H, Sjostedt A. An attenuated strain of the facultative intracellular bacterium Francisella tularensis can escape the phagosome of monocytic cells. Infect. Immun. 71(10), 5940-5950 (2003). (Pubitemid 37205646)
13. Clemens DL, Lee BY, Horwitz MA. Virulent and avirulent strains of Francisella tularensis prevent acidification and maturation of their phagosomes and escape into the cytoplasm in human macrophages. Infect. Immun. 72(6), 3204-3217 (2004). (Pubitemid 38697741)
14. Conlan JW, Shen H, Kuolee R, Zhao X, Chen W. Aerosol-, but not intradermalimmunization with the live vaccine strain of Francisella tularensis protects mice against subsequent aerosol challenge with a highly virulent type A strain of the pathogen by an ab T cell- and interferon g-dependent mechanism. Vaccine 23(19), 2477-2485 (2005). • Shows the importance of T cells in immunity to type A strains. (Pubitemid 40332519)
15. Elkins KL, Cowley SC, Bosio CM. Innate and adaptive immunity to Francisella. Ann. NY Acad. Sci. 1105, 284-324 (2007).
16. Kirimanjeswara GS, Golden JM, Bakshi CS, Metzger DW. Prophylactic and therapeutic use of antibodies for protection against respiratory infection with Francisella tularensis. J. Immunol. 179(1), 532-539 (2007). (Pubitemid 46986570)
17. Baron SD, Singh R, Metzger DW. Inactivated Francisella tularensis live vaccine strain protects against respiratory tularemia by intranasal vaccination in an immunoglobulin A-dependent fashion. Infect. Immun. 75(5), 2152-2162 (2007). (Pubitemid 46744301)
18. Sebastian S, Pinkham JT, Lynch JG et al. Cellular and humoral immunity are synergistic in protection against types A and B Francisella tularensis. Vaccine 27(4), 597-605 (2009). • Used a combination vaccine to enhance protective immunity and demonstrate a role for humoral immunity in protection against type A strains.
19. Van Metre TJ, Kadull P. Laboratoryacquired tularemia in vaccinated individuals: a report of 62 cases. Ann. Intern. Med. 50, 621-632 (1959).
20. Eigelsbach HT, Downs CM. Prophylactic effectiveness of live and killed tularemia vaccines. I. Production of vaccine and evaluation in the white mouse and guinea pig. J. Immunol. 87, 415-425 (1961).
21. Qin A, Mann BJ. Identification of transposon insertion mutants of Francisella tularensis tularensis strain Schu S4 deficient in intracellular replication in the hepatic cell line HepG2. BMC Microbiol. 6, 69 (2006). (Pubitemid 44316096)
22. Su J, Yang J, Zhao D, Kawula TH, Banas JA, Zhang JR. Genome-wide identification of Francisella tularensis virulence determinants. Infect. Immun. 75(6), 3089-3101 (2007). (Pubitemid 46870195)
23. Weiss DS, Brotcke A, Henry T, Margolis JJ, Chan K, Monack DM. In vivo negative selection screen identifies genes required for Francisella virulence. Proc. Natl Acad. Sci. USA 104(14), 6037-6042 (2007). (Pubitemid 47175654)
24. Tempel R, Lai XH, Crosa L, Kozlowicz B, Heffron F. Attenuated Francisella novicida transposon mutants protect mice against wild-type challenge. Infect. Immun. 74(9), 5095-5105 (2006). (Pubitemid 44300427)
25. Maier TM, Casey MS, Becker RH et al. Identification of Francisella tularensis Himar1-based transposon mutants defective for replication in macrophages. Infect. Immun. 75(11), 5376-5389 (2007). (Pubitemid 350033626)
26. Pechous R, Celli J, Penoske R, Hayes SF, Frank DW, Zahrt TC. Construction and characterization of an attenuated purine auxotroph in a Francisella tularensis live vaccine strain. Infect. Immun. 74(8), 4452-4461 (2006). (Pubitemid 44157231)
27. Pechous RD, McCarthy TR, Mohapatra NP et al. A Francisella tularensis Schu S4 purine auxotroph is highly attenuated in mice but offers limited protection against homologous intranasal challenge. PLoS ONE 3(6), e2487 (2008).
28. Bakshi CS, Malik M, Mahawar M et al. An improved vaccine for prevention of respiratory tularemia caused by Francisella tularensis SchuS4 strain. Vaccine 26(41), 5276-5288 (2008). • Shows an attenuated LVS strain provides significant protection against type A strains.
29. Bakshi CS, Malik M, Regan K et al. Superoxide dismutase B gene (sodB)-deficient mutants of Francisella tularensis demonstrate hypersensitivity to oxidative stress and attenuated virulence. J. Bacteriol. 188(17), 6443-6448 (2006). (Pubitemid 44448591)
30. Li J, Ryder C, Mandal M, Ahmed F, Azadi P, Snyder DS et al. Attenuation and protective efficacy of an O-antigen-deficient mutant of Francisella tularensis LVS. Microbiology. 153(Pt 9), 3141-3153 (2007). (Pubitemid 47517074)
31. Conlan JW, Shen H, Webb A, Perry MB. Mice vaccinated with the O-antigen of Francisella tularensis LVS lipopolysaccharide conjugated to bovine serum albumin develop varying degrees of protective immunity against systemic or aerosol challenge with virulent type A and type B strains of the pathogen. Vaccine 20(29-30), 3465-3471 (2002). (Pubitemid 35248070)
32. Fulop M, Mastroeni P, Green M, Titball RW. Role of antibody to lipopolysaccharide in protection against low- and high-virulence strains of Francisella tularensis. Vaccine 19(31), 4465-4472 (2001). (Pubitemid 32718670)
33. Jackson M, Phalen SW, Lagranderie M et al. Persistence and protective efficacy of a Mycobacterium tuberculosis auxotroph vaccine. Infect. Immun. 67(6), 2867-2873 (1999). (Pubitemid 29244702)
34. Sebastian S, Dillon ST, Lynch JG et al. A defined O-antigen polysaccharide mutant of Francisella tularensis live vaccine strain has attenuated virulence while retaining its protective capacity. Infect. Immun. 75(5), 2591-2602 (2007). (Pubitemid 46744351)
35. Kotloff KL, Pasetti MF, Barry EM et al. Deletion in the Shigella enterotoxin genes further attenuates Shigella flexneri 2a bearing guanine auxotrophy in a Phase 1 trial of CVD 1204 and CVD 1208. J. Infect. Dis. 190(10), 1745-1754 (2004). (Pubitemid 39487817)
36. Wang JY, Pasetti MF, Noriega FR et al. Construction, genotypic and phenotypic characterization, and immunogenicity of attenuated DeltaguaBA Salmonella enterica serovar typhi strain CVD 915. Infect. Immun. 69(8), 4734-4741 (2001). (Pubitemid 32674450)
37. Shen H, Chen W, Conlan JW. Mice sublethally infected with Francisella novicida U112 develop only marginal protective immunity against systemic or aerosol challenge with virulent type A or B strains of F. tularensis. Microb. Pathog. 37(2), 107-110 (2004). (Pubitemid 39106845)
38. Quarry JE, Isherwood KE, Michell SL, Diaper H, Titball RW, Oyston PC. A Francisella tularensis subspecies novicida purF mutant, but not a purA mutant, induces protective immunity to tularemia in mice. Vaccine 25(11), 2011-2018 (2007). (Pubitemid 46227681)
39. Kanistanon D, Hajjar AM, Pelletier MR et al. A Francisella mutant in lipid A carbohydrate modification elicits protective immunity. PLoS Pathog. 4(2), e24 (2008). (Pubitemid 351340714)
40. Pammit MA, Raulie EK, Lauriano CM, Klose KE, Arulanandam BP. Intranasal vaccination with a defined attenuated Francisella novicida strain induces gamma interferon-dependent antibody-mediated protection against tularemia. Infect. Immun. 74(4), 2063-2071 (2006).
41. Santic M, Molmeret M, Klose KE, Jones S, Kwaik YA. The Francisella tularensis pathogenicity island protein IglC and its regulator MglA are essential for modulating phagosome biogenesis and subsequent bacterial escape into the cytoplasm. Cell. Microbiol. 7(7), 969-979 (2005). (Pubitemid 40903319)
42. Lai XH, Golovliov I, Sjostedt A. Expression of IglC is necessary for intracellular growth and induction of apoptosis in murine macrophages by Francisella tularensis. Microb. Pathog. 37(5), 225-230 (2004). (Pubitemid 39423958)
43. Twine S, Bystrom M, Chen W et al. A mutant of Francisella tularensis strain SCHU S4 lacking the ability to express a 58-kilodalton protein is attenuated for virulence and is an effective live vaccine. Infect. Immun. 73(12), 8345-8352 (2005). (Pubitemid 41740325)
44. Qin A, Scott DW, Mann BJ. Francisella tularensis Schu S4 disulfide bond formation protein B, (DsbB), but not an RND-type efflux pump, is required for virulence. Infect. Immun. 76(7), 3086-3092 (2008).
45. Qin A, Scott DW, Thompson JA, Mann BJ. Identification of an essential Francisella tularensis subsp. tularensis virulence factor. Infect. Immun. 77(1), 152-161 (2009). • Identifies an avirulent mutant of a type A strain that can act as a protective vaccine.
46. Huntley JF, Conley PG, Rasko DA, Hagman KE, Apicella MA, Norgard MV. Native outer membrane proteins protect mice against pulmonary challenge with virulent type A Francisella tularensis. Infect. Immun. 76(8), 3664-3671 (2008). • Shows significant protection against a type A strain with an acellular vaccine.
47. Roland KL, Tinge SA, Killeen KP, Kochi SK. Recent advances in the development of live, attenuated bacterial vectors. Curr. Opin. Mol. Ther. 7(1), 62-72 (2005). (Pubitemid 40287457)
48. Kopecko DJ, Sieber H, Ures JA et al. Genetic stability of vaccine strain Salmonella typhi Ty21a over 25 years. Int. J. Med. Microbiol. 299(4), 233-246 (2008).
49. Fulop M, Manchee R, Titball R. Role of two outer membrane antigens in the induction of protective immunity against Francisella tularensis strains of different virulence. FEMS Immunol. Med. Microbiol. 13(3), 245-247 (1996). (Pubitemid 26133338)
50. Sjostedt A, Sandstrom G, Tarnvik A. Humoral and cell-mediated immunity in mice to a 17-kilodalton lipoprotein of Francisella tularensis expressed by Salmonella typhimurium. Infect. Immun. 60(7), 2855-2862 (1992).
51. Jia Q, Lee BY, Clemens DL, Bowen RA, Horwitz MA. Recombinant attenuated Listeria monocytogenes vaccine expressing Francisella tularensis IglC induces protection in mice against aerosolized type A F. tularensis. Vaccine 27(8), 1216-1229 (2009). • Demonstrates the successful use of a heterologous bacterial vector, whereby immunization with a single Francisella antigen can elicit protection against respiratory challenge with type A strains.
52. Bruhn KW, Craft N, Miller JF. Listeria as a vaccine vector. Microbes Infect. 9(10), 1226-1235 (2007).
53. Kim SH, Castro F, Gonzalez D, Maciag PC, Paterson Y, Gravekamp C. Mage-b vaccine delivered by recombinant Listeria monocytogenes is highly effective against breast cancer metastases. Br. J. Cancer. 99(5), 741-749 (2008).
54. Angelakopoulos H, Loock K, Sisul DM, Jensen ER, Miller JF, Hohmann EL. Safety and shedding of an attenuated strain of Listeria monocytogenes with a deletion of actA/plcB in adult volunteers: a dose escalation study of oral inoculation. Infect. Immun. 70(7), 3592-3601 (2002). (Pubitemid 34665997)
55. Chen W, Shen H, Webb A, KuoLee R, Conlan JW. Tularemia in BALB/c and C57BL/6 mice vaccinated with Francisella tularensis LVS and challenged intradermally, or by aerosol with virulent isolates of the pathogen: protection varies depending on pathogen virulence, route of exposure, and host genetic background. Vaccine 21(25-26), 3690-3700 (2003). • Describes differences in susceptibility and protection in different mouse backgrounds, and differences in protection against LVS and virulent type A and B strains. (Pubitemid 37345131)